Anti-cancer Mechanism of Polygonati Rhizoma-Lilii Bulbus Based on Network Pharmacology
10.13422/j.cnki.syfjx.20192123
- VernacularTitle:基于网络药理学探讨黄精-百合药对抗癌作用的机制
- Author:
Ting YU
1
;
Zhu YANG
1
;
Feng-xi LONG
1
;
Wen-yu WU
1
;
Jia WANG
1
;
Jin-lin WU
1
;
Dong-xin TANG
1
Author Information
1. Tumor Inheritance and Scientific and Technological Innovation Talents Base of Traditional Chinese Medicine(TCM) in Guizhou Province, Guizhou University of TCM, Guiyang 550002, China
- Publication Type:Research Article
- Keywords:
Polygonati Rhizoma-Lilii Bulbus;
cancer;
network pharmacology;
molecular mechanism
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(5):168-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective::To screen out active ingredients of Polygonati Rhizoma-Lilii Bulbus, and predict the targets and signaling pathways, in order to explore the potential mechanism in treatment of cancer by using network pharmacology. Method::All of active ingredients and targets of Polygonati Rhizoma-Lilii Bulbus were screened out through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Disease targets for cancer were collected through databases of gene-disease associations (DisGeNET) and Online Mendelian Inheritance in Man (OMIM). Then the Omicshare platform was used to match the active ingredients and the targets for treating cancer. And the " drug-active ingredients-disease targets" network was established using Cytoscape 3.7.0 software. The functional protein association networks (String) database was used to construct the protein interaction network of drug pair targets for treating cancer. Finally, the Functional Annotation Bioinformatics Microarray Analysis (DAVID) database was used to analyze the biological functions and metabolic pathways of key targets. Result::A total of 19 active ingredients were screened out, 234 targets were predicted, 6 active ingredients were identified to be related to cancer. The anti-cancer effect was mainly correlated with the regulation of target proteins in treating cancer, such as Akt serine/threonine kinase 1 (Akt1), Jun proto-oncogene, AP-1 transcription factor subunit (JUN), vascular endothelial growth factor A (VEGFA), matrix metallopeptidase-9 (MMP-9), Caspase-3, Fos proto-oncogene, AP-1 transcription factor subunit (FOS), proteoglycans in cancer, estrogen signaling pathway, human immunodeficiency virus 1 infection, hypoxia inducible factor-1 (HIF-1) signaling pathway, tumor necrosis factor(TNF) signaling pathway, microRNAs in cancer and other pathways. Conclusion::The anti-cancer effect of Polygonati Rhizoma-Lilii Bulbus reflects multi-component, multi-target, multi-pathway characteristics of TCM, and provides a scientific basis for explaining the mechanism and material basis of anti-cancer treatment.
